Melane Sampson, Author at BioTuesdays

Developments

Sio Gene presents positive interim Phase 1/2 data in GM1 gangliosidosis

Sio Gene Therapies (NASDAQ:SIOX) presented positive interim data from its ongoing Phase 1/2 study of AXO-AAV-GM1, its adeno-associated viral vector 9-based gene therapy candidate for the treatment of GM1 gangliosidosis...

October 21, 2021

Developments

NeoTX enrolls first patient in Phase 2a NAP trial in NSCLC

Closely held NeoTX Therapeutics of Israel enrolled the first patient in its Phase 2a clinical trial of naptumomab estafenatox (NAP), its lead tumor targeted superantigen candidate, in combination with docetaxel in...

October 20, 2021

Executive Moves

GeneTether bolsters management team to support growth

Closely held GeneTether, a genome editing technology company, named Roland Boivin as CEO, Jean Jen as CFO and Peter Sampson, Ph.D., as VP of research and development. The appointments are intended to further position...

October 19, 2021

Developments

111, Inc. selected to 2021 China Top 20 Internet Healthcare Companies list

111, Inc. (NASDAQ:YI) was selected as one of the 2021 Top 20 Internet Healthcare Enterprises in China for its innovation and promotion in the internet+healthcare field and its transformative platform serving the...

October 15, 2021

Developments

FDA accepts Altamira 510(k) application for Bentrio

Altamira Therapeutics’ (NASDAQ:CYTO) 510(k) application for premarket clearance for its Bentrio nasal spray for protection against airborne allergens was accepted for review by the FDA. The application now moves to a...

October 14, 2021

Developments

Labster to acquire UbiSim in virtual reality training expansion

Labster, a leading platform for virtual labs and interactive science based in Denmark, signed a definitive agreement to acquire UbiSim, a virtual reality training platform for nursing, in a move to further transform...

October 14, 2021

Developments

Supernus Pharma to acquire Adamas Pharma for $400-million plus CVRs

Supernus Pharmaceuticals (NASDAQ:SUPN) agreed to acquire Adamas Pharmaceuticals (NASDAQ:ADMS) in a tender offer for $8.10 a share in cash, or about $400-million plus two non-tradable contingent value rights (CVR). The...

October 11, 2021

Developments

Hirosaki University Hospital to initiate Asensus Senhance Robotic Surgery program

Hirosaki University Hospital agreed to lease and utilize a Senhance Surgical System from Asensus Surgical (NYSE American: ASXC), which is digitizing the interface between surgeon and patient to enhance performance...

October 6, 2021

Developments

VistaGen reports new mechanism of action data for PH94B

VistaGen Therapeutics (NASDAQ:VTGN) announced new mechanism of action data from a preclinical tissue distribution study in laboratory rats demonstrating that a single intranasal administration of radiolabeled carbon-14...

October 5, 2021

Developments

Hepion Pharma drug-drug-interaction study with CRV431 meets all endpoints

Hepion Pharmaceuticals (NASDAQ:HEPA) met all endpoints in a drug-drug-interaction study with its lead drug candidate, CRV431. The randomized, open label study was conducted in 24 healthy volunteers to determine if...

September 29, 2021

Author - Melane Sampson

Sio Gene presents positive interim Phase 1/2 data in GM1 gangliosidosis

NeoTX enrolls first patient in Phase 2a NAP trial in NSCLC

GeneTether bolsters management team to support growth

111, Inc. selected to 2021 China Top 20 Internet Healthcare Companies list

FDA accepts Altamira 510(k) application for Bentrio

Labster to acquire UbiSim in virtual reality training expansion

Supernus Pharma to acquire Adamas Pharma for $400-million plus CVRs

Hirosaki University Hospital to initiate Asensus Senhance Robotic Surgery program

VistaGen reports new mechanism of action data for PH94B

Hepion Pharma drug-drug-interaction study with CRV431 meets all endpoints

Subscribe